GenPhar and US Army Research Institute for Infectious Diseases’ (USAMRIID) article entitled, “Development of a cAdVax-based bivalent Ebola vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus” will be published in March 2006 in the Journal of Virology.

The article discusses the early stages of GenPhar and USAMRIID's challenge tests, when mice vaccinated with the cAdVax vaccine proved 100% protected against lethal challenge with the Ebola virus.

GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a leader in developing and producing prophylactic and therapeutic vaccines to protect against the world’s most dangerous diseases. To reach its goals, GenPhar will leverage the advantage of its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple vaccine products. GenPhar's products are divided into two main areas: vaccines for biodefense and vaccines for chronic infectious diseases (including HIV, hepatitis B and hepatitis C). These products will have a large scale socio-economic impact and transformative effect on current research and treatments. GenPhar was founded in 1999 and is headquartered in Mount Pleasant, South Carolina.

To learn more about GenPhar and its vaccine programs, please contact us.